Biotech firm Nkarta posts Q2 net loss; cash runway into 2029

Nkarta

10/08/2026 21:32

Overview
US biotech firm reported Q2 net loss of $40.4 mln, or $0.54 per share
Company ended Q2 with $243.2 mln in cash and investments, expects runway into 2029
Enrollment continues in Ntrust-1 and Ntrust-2 trials, initial data expected in 2026

Outlook
Nkarta expects current cash balance to fund operations into 2029
Initial clinical data from Ntrust-1 and Ntrust-2 expected to be presented in 2026

Result Drivers
TRIAL ENROLLMENT - Co continued to enroll patients in Ntrust-1 and Ntrust-2 trials at the 4 bln cell dose level across all indications
OUTPATIENT DOSING EXPANSION - Outpatient dosing of NKX019 began at community-based sites, broadening patient access beyond academic centers
SINGLE-AGENT EVALUATION - Trials designed to assess NKX019 as a single agent without supplemental cytokines or antibody-based therapeutics

Company press release: ID:nGNX4hR3rl

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.54
 
Q2 Net Loss
 
$40.37 mln
 
Q2 Cash & Investments
 
$243.2 mln
 
Q2 Loss Per Basic Share
 
$0.54
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Nkarta, Inc. is $11.00, about 356.4% above its August 7 closing price of $2.41

Reuters Recommended Reads
Aug 10 - Cell therapy developer ProKidney's Q2 operating loss widens as trial costs rise
Aug 10 - Metagenomi Q2 net loss widens cash runway seen through 2027
Aug 10 - Olema Pharmaceuticals Q2 net loss widens on higher clinical trial spending

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)